Intuitive Surgical, Protocol: ISI-IRIS-002 , PI: Dr. Stifelman, Title: A Prospective Post-Market Study To Evaluate The Clinical Utility Of IRISTM, A Three-Dimensional (3-D) Anatomical Modeling Software For Pre-Operative Surgical Planning And Intra-Operative Navigation For Nephrectomy Read more
Phase II Trial Of Intravesical Gemcitabine And MK-3475 (Pembrolizumab) In The Treatment Of Patients With BCG-Unresponsive Non-Muscle Invasive Bladder Cancer Read more
A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study To Compare Tivozanib In Combination With Nivolumab To Tivozanib In Subjects With Renal Cell Carcinoma Who Have Progressed Following One Or Two Lines Of Therapy, One Of Which Is An Immune Checkpoint Inhibitor Read more
A Phase II/III Trial Of MEDI4736 (Durvalumab) And Chemotherapy For Patients With High Grade Upper Tract Urothelial Cancer Prior To Nephroureterectomy Read more
A Phase I/II Study Evaluating The Dosing, Safety, Efficacy, And Biological Activity Of Intraperitoneal GEN-1 (IL-12 Plasmid Formulated With PEG-PEI-Cholesterol Lipopolymer) Administered In Combination With Neoadjuvant Chemotherapy (NACT) In Patients Actively Diagnosed With Advanced Epithelial Ovarian, Fallopian Tube Or Primary Peritoneal Cancer Read more
Phase III Randomized Adjuvant Study Of Pembrolizumab In Muscle Invasive And Locally Advanced Urothelial Carcinoma (AMBASSADOR) Versus Observation Read more
Phase II Study Of Front Line Therapy With Nivolumab And Salvage Nivolumab + Ipilimumab In Patients With Advanced Renal Cell Carcinoma. HCRN: GU16-260 Read more
A Phase 2 Study Of Cabozantinib In Combination With Atezolizumab As Neoadjuvant Treatment For Muscle-Invasive Bladder Cancer (ABATE) Read more
A Phase II Clinical Trial To Study The Efficacy And Safety Of Pembrolizumab (MK-3475) In Subjects With High Risk Non-Muscle Invasive Bladder Cancer (NMIBC) Unresponsive To Bacillus Calmette-Guerin (BCG) Therapy Read more
